The administration of ODZ10117 dramatically decreased the tumor population and the levels of active STAT3, CSC markers such as NESTIN and SOX2, and MES-associated genes FN and ITGAV without significantly affecting the body weight compared to the vehicle-treated control group (Figure 6B and Figure S4). The gene discussed is SOX2; the disease is neoplasm.